0001179110-15-009895.txt : 20150616 0001179110-15-009895.hdr.sgml : 20150616 20150616161942 ACCESSION NUMBER: 0001179110-15-009895 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150615 FILED AS OF DATE: 20150616 DATE AS OF CHANGE: 20150616 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CATLIN AVERY W CENTRAL INDEX KEY: 0001255348 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 15934559 MAIL ADDRESS: STREET 1: 241 CENTRAL STREET CITY: HINGHAM STATE: MA ZIP: 02043 4 1 edgar.xml FORM 4 - X0306 4 2015-06-15 0 0000744218 Celldex Therapeutics, Inc. CLDX 0001255348 CATLIN AVERY W C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD HAMPTON NJ 08827 0 1 0 0 Sr. VP & CFO Common Stock 2015-06-15 4 M 0 25000 8.52 A 49609 D Common Stock 2015-06-15 4 S 0 25000 24.5901 D 24609 D Non-Qualified Stock Option 8.52 2015-06-15 4 M 0 25000 0 D 2010-01-06 2019-01-06 Common Stock 25000 0 D The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12,2015. The options exercised and sold by the Reporting Person were due to expire January 6,2019. 25% of the shares vested on January 6, 2010 and the remainder vested quarterly (in equal amounts) over the subsequent 12 quarters. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.35 to $25.23, inclusive. The Reporting Person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. /s/ Anthony S. Marucci, attorney in fact for Avery W. Catlin 2015-06-16